Drug usage and costs of inpatients with chronic obstructive pulmonary disease in Karamay Central Hospital in 2014_Chinese Journal of Evidence-Based Medicine

Authors：

PENG Xueqin ¹ , YU Jiajie ² ,  ZHANG Weidong ¹ ,  LI Youping ² , WU Min ¹ , XU Ting ³ , WANG Fei ¹ , LU Jing ³ , ZHANG Shengzhao ¹ , SUN Xin ² , SU Guanyue ²

1. Department of Pharmacy, Karamay Central Hospital, Karamay, 834000, P.R.China;
2. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

ZHANG Weidong, Email: 0990end@sohu.com.cn; LI Youping, Email: yzmylab@hotmail.com

Keywords：

Inpatients; Chronic obstructive pulmonary disease; Evidence-based pharmacy; Rational drug use

DOI：

10.7507/1672-2531.201611099

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate drug usage and costs of chronic obstructive pulmonary disease (COPD) inpatients in Karamay Central Hospital in 2014 and to provide evidence and reference for evidence-based pharmacy study on COPD. Methods The information of drug use and expenditure of COPD inpatients were collected from the hospital information system (HIS). We analyzed the data including frequency, proportion and cumulative proportion by Excel 2007 software. Results A total of 194 inpatients with COPD/AECOPD were included in Karamay Central Hospital in 2014, the average age was 74.28±7.81 years old. Fifty-three drugs were used for COPD treatment; the total frequency were 1 798 times and per capita cost was 7 419.78 yuan. The top three used drugs were budesonide suspension, montelukast tablets and methylprednisolone injection. In total expenditure, the cost of piperacillin-tazobactam, imipenem/cilastatin and moxifloxacin injection ranked top three. Conclusion The top 3 used drugs are budesonide suspension, montelukast tablets and methylprednisolone injection for COPD inpatients in Karamay Central Hospital in 2014, while the top 3 total expenditure drugs are piperacillin-tazobactam, imipenem/cilastatin and moxifloxacin injection.

Citation： PENG Xueqin, YU Jiajie, ZHANG Weidong, LI Youping, WU Min, XU Ting, WANG Fei, LU Jing, ZHANG Shengzhao, SUN Xin, SU Guanyue. Drug usage and costs of inpatients with chronic obstructive pulmonary disease in Karamay Central Hospital in 2014. Chinese Journal of Evidence-Based Medicine, 2017, 17(8): 888-891. doi: 10.7507/1672-2531.201611099 Copy

1.	世界衛生組織. 前十位死亡原因. 實況報道, 第310號, 2014. Available at: http://www.who.int/mediacentre/factsheets/fs310/zh/.
2.	慢性阻塞性肺疾病急性加重(AECOPD)診治專家組. 慢性阻塞性肺疾病急性加重(AECOPD)診治中國專家共識(草案). 中華哮喘雜志(電子版), 2013, 7(1): 1.
3.	Miravitlles M, Jose Soler-Cataluna J, Calle MA, et al. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol, 2012, 48(7): 247-257.
4.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013年修訂版). 中國醫學前沿雜志(電子版), 2014, 6(2): 67-80.
5.	Kankaanranta H, Harju T, Kilpel?inen M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol, 2015, 116(4): 291-307.
6.	GOLD Executive Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2015). Available at: www.gold.com.
7.	Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society guideline. Chest, 2015, 147(4): 894-942.
8.	GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2016). Available at: www.gold.com.
9.	胡付品, 朱德妹, 汪復, 等. 2013 中國 CHINET 細菌耐藥性監測. 中國感染與化療雜志, 2014, 14(5): 365-374.

1. 世界衛生組織. 前十位死亡原因. 實況報道, 第310號, 2014. Available at: http://www.who.int/mediacentre/factsheets/fs310/zh/.
2. 慢性阻塞性肺疾病急性加重(AECOPD)診治專家組. 慢性阻塞性肺疾病急性加重(AECOPD)診治中國專家共識(草案). 中華哮喘雜志(電子版), 2013, 7(1): 1.
3. Miravitlles M, Jose Soler-Cataluna J, Calle MA, et al. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol, 2012, 48(7): 247-257.
4. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013年修訂版). 中國醫學前沿雜志(電子版), 2014, 6(2): 67-80.
5. Kankaanranta H, Harju T, Kilpel?inen M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol, 2015, 116(4): 291-307.
6. GOLD Executive Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2015). Available at: www.gold.com.
7. Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society guideline. Chest, 2015, 147(4): 894-942.
8. GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2016). Available at: www.gold.com.
9. 胡付品, 朱德妹, 汪復, 等. 2013 中國 CHINET 細菌耐藥性監測. 中國感染與化療雜志, 2014, 14(5): 365-374.

Chinese Journal of Evidence-Based Medicine

Drug usage and costs of inpatients with chronic obstructive pulmonary disease in Karamay Central Hospital in 2014

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content